The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2022 | Influence of sidedness on prognosis and treatment in mCRC
Chiara Cremolini, MD, PhD, University of Pisa, Pisa, Italy, discusses the impact of sidedness on the prognosis and treatment of patients with metastatic colorectal cancer (mCRC). Right-sided tumors are more aggressive and patients experience a poorer prognosis. Patients with right-sided tumors are also associated with increased molecular alterations driving intrinsic resistance to anti-EGFR monoclonal antibodies. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
